checkAd

     153  0 Kommentare ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza as a Treatment for AADC Deficiency - Seite 3

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d375ef5e-925f-4976 ... 

    CONTACT: Contact:

Media Contact:
Jacqueline Keller, Vice President of Marketing
(888) 287-9109 ext. 4
info@clearpointneuro.com

Investor Relations:
Danilo D’Alessandro, Chief Financial Officer
(888) 287-9109 ext. 3
ir@clearpointneuro.com

    Lesen Sie auch


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza as a Treatment for AADC Deficiency - Seite 3 If Approved, Upstaza Would be the First Disease-Modifying Treatment for AADC Deficiency in the United StatesSOLANA BEACH, Calif., March 19, 2024 (GLOBE NEWSWIRE) - ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and …